Janney ups target on NPS Pharma, sees off-label Gattex reimbursement • 9:53 AM
•Janney sees evidence of off-label reimbursement for the NPS Pharmaceuticals' (NPSP +2%) SBS treatment Gattex. That's good news considering there are questions regarding insurer coverage push back.
•Analyst Jim Molloy speculates Cigna and Blue Cross are already reimbursing off-label use. Janney's new price target for NPSP is $45.